If you’re going to ADLM 2024 in Chicago, be sure to meet with us while you’re there. Our Medical Devices & Diagnostics Research team are at booth #5237 and looking forward to discussing challenges and solutions in vitro diagnostic device development. https://ow.ly/x48o50SwJ7a
About us
Since our foundation in Dublin, Ireland in 1990, our mission has been to help our clients to accelerate the development of drugs and devices that save lives and improve quality of life. We do this by delivering best in class information, solutions and performance, with an unyielding focus on quality at all times. We offer a full range of consulting, development and commercialisation services from a global network of offices in 53 countries. We focus our innovation on the factors that are critical to our clients – reducing time to market, reducing cost, and increasing quality – and our global team of experts has extensive experience in a broad range of therapeutic areas.
- Website
-
http://www.iconplc.com
External link for ICON plc
- Industry
- Biotechnology Research
- Company size
- 10,001+ employees
- Headquarters
- Dublin
- Type
- Public Company
- Specialties
- Medical Device, Therapeutics, Government and Public Health Solutions, Clinical Research Services, Commercialisation and Outcomes, Oncology, Value Based Healthcare, Clinical Trials, Patient Recruitment, Innovation, Regulatory Affairs, Strategic Consulting, Medical Affairs, and Global Patient Insights & Engagement
Locations
Employees at ICON plc
Updates
-
In the first half of 2024, ICON won a number of leading business and industry awards recognising the company’s leadership position in the clinical research industry, in addition to its efforts in inclusion, sustainability and as an employer of choice. Read more here: https://ow.ly/jryj50SywHA #ICONCares #leadership #clinicalresearch
-
-
Integrating human-enabled AI into site selection processes allows sponsors to benefit from an ecosystem approach. Our new blog delves into the transformative power of One Search, our AI-driven system that redefines site suitability and ecosystem connectedness. Learn how we leverage AI to make informed decisions, improve diversity in trials and unlock untapped site potential: https://ow.ly/wiTY50StttG #ClinicalResearch #AI #data #innovation
-
-
Increasing numbers of IPF studies and a limited pipeline of participants mean researchers need novel strategies for drug development. Learn how to navigate the changing landscape of research on this rare disease in this blog from our experts. https://ow.ly/VVtR50SwIri
-
-
Early phase clinical research is key to refining the safety profile of new drugs and proof of concept, expanding on the data gathered in preclinical studies. Ensuring participant safety requires strategic planning at multiple levels, from protocol and dose escalation to personnel training. ICON is continuously implementing proactive participant safety measures to effectively mitigate risks in early phase studies, with regular safety drills being performed by both clinic and hospital staff to ensure highly coordinated response and execution. We have also introduced the Modified Early Warning Score (MEWS) - this is designed to identify disturbances in vital parameters and prevent further serious risk to the trial participant. Read our blog to find out more. https://ow.ly/eG6x50StFvZ #earlyphase
-
-
ICON rated as having exceeded customer expectations in the Compatibility category in the CRO Leadership Awards 2024. How we partner with sponsors is important to us – flexible, collaborative and a shared commitment to clinical developments goals. Learn more: https://ow.ly/x3aV50Sq3HZ #CROLeadershipAward #ExcellenceInClinicalResearch
-
-
At ICON, we understand that work-life balance is not just about life outside the office—it’s about creating a balanced, enjoyable environment at work too. Last week, our Talent Acquisition team in Reading had an excellent team-building lunch. They enjoyed a "potluck" meal and had a great time painting portraits of each other. It was a fantastic opportunity to catch up and share some laughs, especially when they revealed their masterpieces! Curious about a career at ICON? Check out our open opportunities: https://ow.ly/MIx350SwVI7
-
-
-
-
-
+2
-
-
Stay informed about the evolving landscape of cancer treatment with our latest whitepaper. Delve into strategies for commercialising oncology treatments for young adults and navigate regulatory challenges effectively. Click here to download: https://ow.ly/6mQw50Svem4 #Oncology #Healthcare #ClinicalResearch
-
-
The 13th Annual #CTO East Coast conference is just around the corner! Plan your visit and meet the ICON team at the Boston Marriott Burlington to discover what are the effective strategies for oncology trial operations that ensure trials to run smoothly and within budget. https://ow.ly/Ux1150SwJrV
-
-
The clinical management of CML requires the identification of each patient’s BCR::ABL1 transcript type at diagnosis and the monitoring of its expression and potential TKI resistance mutations during treatment. Two challenges to this clinical use case are the detection of atypical BCR::ABL1 transcript types and the sensitive and reliable detection of TKI resistant mutations from common and atypical transcripts. ICON Specialty Laboratories developed a novel RNA-based NGS assay, Dup-Seq BCR::ABL1, to address these two challenges in the molecular testing of CML patients. Read more on this approach in the latest article from Dr. Jin Li. https://ow.ly/Tkhb50S9kIO
-